tada-images-shutterstock

16 November 2023AmericasMarisa Woutersen

Cancer specialist to pay $83.4m over DNA sequencing infringement

TwinStrand Biosciences and the University of Washington win patent infringement case related to DNA mutation technology.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Biotechnology

Force pharma companies to provide drugs for rare cancer trials, UK govt told

30 January 2024 MHRA 'should regulate' the release of drugs for clinical trials for innovative cancer treatments | Medical experts lambast big pharma’s unacceptable lack of involvement in Glioblastoma campaign | Forcing companies will ‘undermine public trust’ says pharma body.

Guardant holds on to diagnostics patent following TwinStrand challenge

1 February 2024 PTAB says claims of genetic disease testing patent are not obvious | Rival biotech firm denied petition for invalidation.

More on this story

Guardant holds on to diagnostics patent following TwinStrand challenge

1 February 2024 PTAB says claims of genetic disease testing patent are not obvious | Rival biotech firm denied petition for invalidation.

Biotechnology

Force pharma companies to provide drugs for rare cancer trials, UK govt told

30 January 2024 MHRA 'should regulate' the release of drugs for clinical trials for innovative cancer treatments | Medical experts lambast big pharma’s unacceptable lack of involvement in Glioblastoma campaign | Forcing companies will ‘undermine public trust’ says pharma body.

More on this story

Guardant holds on to diagnostics patent following TwinStrand challenge

1 February 2024 PTAB says claims of genetic disease testing patent are not obvious | Rival biotech firm denied petition for invalidation.

Biotechnology

Force pharma companies to provide drugs for rare cancer trials, UK govt told

30 January 2024 MHRA 'should regulate' the release of drugs for clinical trials for innovative cancer treatments | Medical experts lambast big pharma’s unacceptable lack of involvement in Glioblastoma campaign | Forcing companies will ‘undermine public trust’ says pharma body.

More features

Fed Circ orders Teva to delist five patents from Orange Book

Sarepta wins $115M in patent dispute over muscular dystrophy drug

Novartis shields eye-drop patent at European Patent Office

CREATES Act unfairly tips the scales to generics

LSPN launches its first-ever US awards to celebrate life sciences leaders

Pharma giants seek closure on COVID-19 vaccine rows

How Inhibrx defended a $450m damages suit

Foley & Lardner adds litigation and transaction expert in New York